Try a new search

Format these results:

Searched for:

person:ahmadh05

in-biosketch:true

Total Results:

6


Real World Treatment Patterns and Treatment Persistence among Ulcerative Colitis and Crohn's Disease Patients in the Corrona Inflammatory Bowel Disease National Registry [Meeting Abstract]

Sauk, J S; Horst, S; Hudesman, D P; Zhuo, J; Ahmad, H; Sreih, A; Harrison, R W; MacKey, R H; Crabtree, M; Emeanuru, K; Cross, R K
INTRODUCTION: The treatment paradigm for inflammatory bowel disease (IBD) has become increasingly complex with more treatment options available. We evaluated treatment sequence and duration in recent real-world (RW) patients with ulcerative colitis (UC) or Crohn's disease (CD) in a large US IBD registry.
METHOD(S): We conducted a retrospective analysis of patients enrolled in the Corrona IBD Registry from 5/3/17 to 12/31/18 with a diagnosis of UC or CD on 1/1/2014 or later. Demographics, clinical characteristics, and prior treatment history were obtained at enrollment. Prescribed therapies were divided into the following categories: biologics (BIO; adalimumab, certolizumab, golimumab, infliximab, natalizumab, ustekinumab, vedolizumab), immunosuppressants (IST; methotrexate, 6-mercaptopurine, azathioprine, tacrolimus, cyclosporine), 5-aminosalicylic acids (ASAs), corticoste-roids (CSs), or a combination of 2 or more of the above. Following a stepwise approach, once patients' treatments graduated to IST or BIO, use of ASA therapy was not considered a change in therapy state. Median (Q1, Q3) duration of treatment for each therapy, across all lines of treatment, was reported.
RESULT(S): 196 UC and 124 CD patients were included in the analysis. Demographics at enrollment are summarized (Table 1). Among UC patients, 81% of first-line (1L) therapy was ASA (38.8%), ASA 1 CS (31.6%), or CS (10.7%), followed by BIO 1 CS (8.2%) and BIO (5.6%; Table 2). Among the 45% of patients with UC who received second-line (2L) therapy, BIO and BIO 1 CS were most common Fewer than 30% of patients were prescribed $3L of therapy. Overall, the longest median duration of treatment was BIO 1 IST (27.6 months [mo]) and BIO 1 IST 1 CS (11.0 mo; Table 3). Among CD patients, 51% of 1L therapy was ASA (21.0%), ASA 1 CS (17.7%), or CS (12.1%), followed by BIO (20.2%; Table 2). 2L therapy was received by 41% of CD patients and 20% were prescribed $3L of therapy. 1L treatment with ASA had a short treatment duration. Longer median durations of treatment were seen for combination treatment such as BIO 1 IST 1 CS (17.8 mo) and BIO 1 IST (10.5 mo; Table 3).
CONCLUSION(S): This RW registry provides insight into treatment sequencing. BIO was commonly a 2L therapy for UC patients, and had higher use as a 1L therapy for CD patients. Although a combination of therapies was not commonly used in practice as 1L or 2L therapy, it had the longest treatment duration. Use of 1L ASA treatment in CD was high despite treatment guidelines, which may explain short treatment durations
EMBASE:633657696
ISSN: 1572-0241
CID: 4718802

Impact of Video Coaching on Ophthalmology Resident Capsulorhexis Performance in Cataract Surgery [Meeting Abstract]

Lo, Danielle; Main, Michael; Patel, Priya; Ahmad, Habeeb
ISI:000488628101077
ISSN: 0146-0404
CID: 4154182

Bilateral Limbal Keratin-Associated Amyloidosis

Charles, Norman C; Belinsky, Irina; Ahmad, Habeeb
Conjunctival amyloid is usually of the immunoglobulin light chain (AL) variety. The authors report an exceptional case of bilateral limbal amyloid deposits that were identified by mass spectrometry as keratin-related specifically regarding to basal keratinocyte keratins 5 and 14. Cytokeratin-related amyloid has been described by immunohistochemical analysis of formalin-fixed cutaneous and mucous membrane lesions but not ocular tissues. The conjunctival lesion in the right eye contained intraepithelial dyskeratotic cells that extended to the surface, causing a lacy leukoplakia on clinical examination. The authors excluded the diagnosis of hereditary benign intraepithelial dyskeratosis in this patient. Collection of patient data and all protected patient health information was compliant with the Health Insurance Portability and Accountability Act.
PMID: 29505468
ISSN: 1537-2677
CID: 2973602

Beta-blockade affects simulator scores [Letter]

Pointdujour, Renelle; Ahmad, Habeeb; Liu, Margaret; Smith, Edward; Lazzaro, Douglas
PMID: 21889664
ISSN: 1549-4713
CID: 1891602

Novel use of trypan blue in ocular surface staining: redefining implications for this vital dye

Ambrosio, Renato, Jr; Ahmad, Habeeb; Caldas, Diogo; Caiado Canedo, Ana Laura; Valbon, Bruno; Guerra, Frederico Procopio; de Souza Lima, Acacio Alves
Different applications of trypan blue (TB) for intraocular surgery have been reported, with very high levels of safety and efficacy. We describe the use of TB as an alternative vital dye for staining the ocular surface to assess the integrity of superficial cell layers of the cornea and the surface environment. This facilitates the diagnosis of various ocular surface disorders, including screening for dry eye disease (DED) among refractive and cataract patients. TB staining properties are different from fluorescein and both are stable in a solution, so that a double staining technique is introduced.
ISI:000300059700014
ISSN: 0034-7280
CID: 2246062

Images in clinical medicine. Schnyder's crystalline corneal dystrophy [Case Report]

Ahmad, Habeeb; Heur, Martin
PMID: 20647202
ISSN: 1533-4406
CID: 2246052